RankAlpha logo
Back to Rankings

MEDP

MedpaceD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Primary evidence is fundamentally constructive: Q1 revenue rose 26.5% to $706.6 million, net new awards rose 23.7% to $618.4 million, EBITDA rose 25.9% to $149.4 million, and operating cash flow was $151.8 million [#SEC-8K-2026-04-22]. If Q2 shows book-to-bill normalization and unchanged or better guidance, the stock can regain a premium multiple.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
Clinical CRO competition remains intense; Medpace identifies IQVIA, ICON, PPD/Thermo Fisher, Fortrea, and specialty/regional CROs as key competitors [#10-K-2026-02-10].
Momentum
89
Value
60
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $503.00 · Bull $540.00 · Bear $395.00Analysis 2026-06-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $674.75
Why
Momentum89 · Δ7d +1.7
Value60 · Δ7d -0.4
Sentiment25 · Δ7d -7.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.4.

Contradictions & invalidation

  • • Clinical CRO competition remains intense; Medpace identifies IQVIA, ICON, PPD/Thermo Fisher, Fortrea, and specialty/regional CROs as key competitors [#10-K-2026-02-10].
  • • Leadership changes around the President role and expanded operations leadership create execution-monitoring risk even though filings say the departure was not due to disagreement.
  • • The near-term debate is that Q1 book-to-bill was only 0.88x and net income margin fell to 17.5% from 20.5% a year earlier, while the President transition and new operations structure add an execution variable [#SEC-8K-2026-04-22] [#8-K-2026-06-04].

Catalyst clock

2026-07-22

Q2 2026 print will test awards momentum and book-to-bill recovery

Lead driver: Value · See fundamentals
Momentum
89
8% active weight
Current posture
7d trendFlat
Δ7d
+1.7
Δ21d
+9.7
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-1.1
Sentiment
25
45% active weight
Current posture
7d trendSoftening
Δ7d
-7.1
Δ21d
-15.0
Why this grade

Composite grade D. Momentum 88.8 / Value 60.4 / Sentiment 25.3

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-18. Scenario method

B+
Bull case
30%
Probability
Target price
$540.00
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$503.00
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$395.00
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$18.93B
Beta
1.42
Shares Out
27.97M
P/E (TTM)
41.0
P/S (TTM)
7.01
P/FCF (TTM)
24.42
Rev YoY
+17.2%
EPS YoY
+37.2%
Gross Margin
+27.8%
Op Margin
+21.0%
Net Debt
-$360.2M
Current Ratio
0.73
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data